Does cannabis use substitute for opioids? A preliminary exploratory survey in opioid maintenance patients
AbstractVarious studies showed that people with substance use disorder use cannabis to reduce withdrawal or dose of their main drug. Using a questionnaire about their cannabis use, 118 participants in an opioid maintenance treatment (OMT) in Germany were examined regarding this strategy. 60% reported to use cannabis. Of those, 72% were using cannabis in the suggested way. Cannabis was used to substitute for, e.g., heroin (44.8%) and benzodiazepines (16.4%). We also asked for an estimation of how good cannabis was able to substitute for several substances (in German school grades (1 till 6)); heroin average grade: 2.6  ±...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Post-COVID breathlessness: a mathematical model of respiratory processing in the brain
AbstractBreathlessness is among the most common post-COVID symptoms. In a considerable number of patients, severe breathlessness cannot be explained by peripheral organ impairment. Recent concepts have described how such persistent breathlessness could arise from dysfunctional processing of respiratory information in the brain. In this paper, we present a first quantitative and testable mathematical model of how processing of respiratory-related signals could lead to breathlessness perception. The model is based on recent theories that the brain holds an adaptive and dynamic internal representation of a respiratory state t...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication
AbstractDetermining peripheral modulation of the endocannabinoid system (ECS) may be important for differentiating individuals with schizophrenia. Such differentiation can also be extended to subgroups of individuals, those who use cannabis and antipsychotic medications, particularly those who are treatment resistant. Patients and controls were recruited from the outpatient clinic of the Psychosis Group of the University of S ão Paulo, Brazil. A final sample of 93 individuals was divided into 3 groups: patients with schizophrenia using clozapine (treatment-resistant) (n = 29), patients with schizophrenia using another...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Cannabis use, health problems, and criminal offences in Germany: national and state-level trends between 2009 and 2021
AbstractThe German federal government plans to decriminalise cannabis. The impact of this policy on use prevalence, cannabis-related health and legal problems cannot be fully anticipated and should be viewed in context with current trends. We used routine data on (a) cannabis use (population-based surveys), (b) cannabis-related diagnoses (ICD-10 code F12) in outpatient medical settings and (c) minor law offences (registered violations against the narcotics law for possessing small amounts) to analyse age and sex-specific trends by federal state between 2009 and 2021. To enable comparisons across time and federal state besi...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

The impact of aerobic endurance training on cognitive performance in schizophrenic inpatients in a clinical routine setting
AbstractThe primary aim of this study was to investigate the impact of aerobic endurance training in schizophrenic inpatients on cognitive performance in a clinical routine setting. Of secondary interest was the influence on psychopathological symptoms. A total of 31 schizophrenic inpatients were randomly assigned to receive either controlled endurance training or occupational therapy. The experimental group underwent endurance training of 20 –30 min each, 3 times per week for a total of up to 22 training sessions. The control group received about 90 min of occupational therapy, 2–3 times per week for up to 22 sessio...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Does cannabis use substitute for opioids? A preliminary exploratory survey in opioid maintenance patients
AbstractVarious studies showed that people with substance use disorder use cannabis to reduce withdrawal or dose of their main drug. Using a questionnaire about their cannabis use, 118 participants in an opioid maintenance treatment (OMT) in Germany were examined regarding this strategy. 60% reported to use cannabis. Of those, 72% were using cannabis in the suggested way. Cannabis was used to substitute for, e.g., heroin (44.8%) and benzodiazepines (16.4%). We also asked for an estimation of how good cannabis was able to substitute for several substances (in German school grades (1 till 6)); heroin average grade: 2.6  ±...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Post-COVID breathlessness: a mathematical model of respiratory processing in the brain
AbstractBreathlessness is among the most common post-COVID symptoms. In a considerable number of patients, severe breathlessness cannot be explained by peripheral organ impairment. Recent concepts have described how such persistent breathlessness could arise from dysfunctional processing of respiratory information in the brain. In this paper, we present a first quantitative and testable mathematical model of how processing of respiratory-related signals could lead to breathlessness perception. The model is based on recent theories that the brain holds an adaptive and dynamic internal representation of a respiratory state t...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication
AbstractDetermining peripheral modulation of the endocannabinoid system (ECS) may be important for differentiating individuals with schizophrenia. Such differentiation can also be extended to subgroups of individuals, those who use cannabis and antipsychotic medications, particularly those who are treatment resistant. Patients and controls were recruited from the outpatient clinic of the Psychosis Group of the University of S ão Paulo, Brazil. A final sample of 93 individuals was divided into 3 groups: patients with schizophrenia using clozapine (treatment-resistant) (n = 29), patients with schizophrenia using another...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 19, 2024 Category: Neuroscience Source Type: research

Evolution of the profiles of new psychotropic drug users before and during the COVID-19 crisis: an original longitudinal approach through multichannel sequence analysis using the French health-care database
This study is one of the first to analyze the profile of psychotropic treatment users during the COVID-19 crisis. Our analysis sheds light on changes in patterns of psychotr opic drug use during the COVID-19 pandemic, possibly associated with changes in prescribing conditions and mental health conditions during the crisis. This study also provides an example of the application of an innovative longitudinal analysis methodology in the field of pharmacoepidemiology. (Source: European Archives of Psychiatry and Clinical Neuroscience)
Source: European Archives of Psychiatry and Clinical Neuroscience - March 18, 2024 Category: Neuroscience Source Type: research

Predictors of effective therapy among individuals with Cannabis Use Disorder: a review of the literature
Eur Arch Psychiatry Clin Neurosci. 2024 Mar 16. doi: 10.1007/s00406-024-01781-4. Online ahead of print.ABSTRACTTreatment demand for Cannabis Use Disorder (CUD) has increased in the past decade in almost all European countries, and CUD is currently the most common reason for first-time drug-related treatment admission in the European Union. Even though several therapeutic approaches have been shown to benefit individuals with CUD, there is a lack of knowledge regarding factors associated with effective therapy and the underlying mechanisms of change among individuals with CUD presenting for treatment. The aim of the present...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 17, 2024 Category: Psychiatry Authors: Daniel Feingold Dana Tzur Bitan Marica Ferri Eva Hoch Source Type: research

Association between psychiatric admissions in patients with schizophrenia and IL-6 plasma levels polygenic score
Eur Arch Psychiatry Clin Neurosci. 2024 Mar 16. doi: 10.1007/s00406-024-01786-z. Online ahead of print.ABSTRACTSchizophrenia diagnosis and admission history were associated with a polygenic score (PGS) for schizophrenia based on a subset of variants that act by modifying the expression of genes whose expression is also modified by antipsychotics. This gene set was enriched in cytokine production. Interleukin-6 (IL-6) is the only cytokine whose plasma levels were associated both with schizophrenia diagnosis and with acute decompensations in the largest meta-analysis. Therefore, we hypothesized that an IL-6 PGS, but not othe...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 16, 2024 Category: Psychiatry Authors: Fernando Facal Manuel Arrojo Mario P áramo Javier Costas Source Type: research

Proinflammatory cytokine levels, cognitive function, and suicidal symptoms of adolescents and young adults with major depressive disorder
Eur Arch Psychiatry Clin Neurosci. 2024 Mar 16. doi: 10.1007/s00406-024-01780-5. Online ahead of print.ABSTRACTWhether proinflammatory cytokine dysregulation and cognitive dysfunction are associated with suicidal symptoms in adolescents and young adults with major depressive disorder (MDD) remains uncertain. We assessed the cognitive function and proinflammatory cytokine levels of 43 and 51 patients aged 15-29 years with MDD and severe and mild suicidal symptoms, respectively, as well as those of 85 age- and sex-matched healthy controls. Specifically, we measured serum levels of C-reactive protein, tumor necrosis factor-α...
Source: European Archives of Psychiatry and Clinical Neuroscience - March 16, 2024 Category: Psychiatry Authors: Mu-Hong Chen Ya-Mei Bai Ju-Wei Hsu Kai-Lin Huang Shih-Jen Tsai Source Type: research